Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab.
Incorvaia L, Dimino A, Algeri L, Brando C, Magrin L, De Luca I, Pedone E, Perez A, Sciacchitano R, Bonasera A, Bazan Russo TD, Li Pomi F, Peri M, Gristina V, Galvano A, Giuffrida D, Fazio I, Toia F, Cordova A, Florena AM, Giordano A, Bazan V, Russo A, Badalamenti G. Incorvaia L, et al. Among authors: gristina v. Front Oncol. 2023 Apr 17;13:1141500. doi: 10.3389/fonc.2023.1141500. eCollection 2023. Front Oncol. 2023. PMID: 37139149 Free PMC article.
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).
Incorvaia L, Fanale D, Badalamenti G, Barraco N, Bono M, Corsini LR, Galvano A, Gristina V, Listì A, Vieni S, Gori S, Bazan V, Russo A. Incorvaia L, et al. Among authors: gristina v. Adv Ther. 2019 Oct;36(10):2600-2617. doi: 10.1007/s12325-019-01057-7. Epub 2019 Aug 20. Adv Ther. 2019. PMID: 31432460 Free PMC article. Review.
Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis.
Galvano A, Castiglia M, Rizzo S, Silvestris N, Brunetti O, Vaccaro G, Gristina V, Barraco N, Bono M, Guercio G, Graceffa G, Fulfaro F, Gori S, Bazan V, Russo A. Galvano A, et al. Among authors: gristina v. Cancers (Basel). 2020 Feb 26;12(3):534. doi: 10.3390/cancers12030534. Cancers (Basel). 2020. PMID: 32110977 Free PMC article. Review.
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score.
Galvano A, Peri M, Guarini AA, Castiglia M, Grassadonia A, De Tursi M, Irtelli L, Rizzo S, Bertani A, Gristina V, Barraco N, Russo A, Natoli C, Bazan V. Galvano A, et al. Among authors: gristina v. Ther Adv Med Oncol. 2020 Aug 11;12:1758835920942378. doi: 10.1177/1758835920942378. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32849916 Free PMC article.
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials.
Galvano A, Gristina V, Malapelle U, Pisapia P, Pepe F, Barraco N, Castiglia M, Perez A, Rolfo C, Troncone G, Russo A, Bazan V. Galvano A, et al. Among authors: gristina v. ESMO Open. 2021 Jun;6(3):100124. doi: 10.1016/j.esmoop.2021.100124. Epub 2021 Apr 30. ESMO Open. 2021. PMID: 33940346 Free PMC article. Review.
Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses.
Gristina V, Galvano A, Castellana L, Insalaco L, Cusenza S, Graceffa G, Iacono F, Barraco N, Castiglia M, Perez A, Rizzo S, Russo A, Bazan V. Gristina V, et al. Ther Adv Med Oncol. 2021 Jul 21;13:17588359211018018. doi: 10.1177/17588359211018018. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34646363 Free PMC article.
46 results